LPL approves up to Rs 49.5 crore for its Dubai subsidiary

Dr. Lal PathLabs Limited has approved up to Rs 49.5 crore of cash investment in LPL Dubai, including up to Rs 30 crore for further investment in Sunshine Healthcare in Ghana. The transaction is expected to be completed by March 31, 2027, subject to regulatory approvals where required.

How much is LPL investing through Dubai?

LPL plans to invest up to Rs 49.5 crore in Dr. Lal PathLabs FZCO, Dubai, which will remain its wholly owned subsidiary after the transaction. The consideration will be paid in cash, and LPL Dubai was created to make strategic investments in diagnostics and allied activities, including potential acquisitions, tie-ups and joint ventures.

Up to Rs 30 crore of the Rs 49.5 crore ceiling is for further investment by LPL Dubai in Sunshine Healthcare Limited. The stated purpose of the wider funding is to meet LPL Dubai’s business and operational requirements, including its further investment in Sunshine Healthcare. The remaining Rs 19.5 crore is the arithmetic difference between the total ceiling and the specified Sunshine Healthcare amount, but LPL did not separately allocate that balance in the disclosure.

The Rs 49.5 crore maximum commitment is below LPL’s standalone cash and cash equivalents of Rs 279.1 crore as of September 30, 2026. LPL also reported bank balances other than cash equivalents of Rs 701.2 crore and current investments of Rs 490 crore on that date, according to the accompanying standalone statement of assets and liabilities.

What is LPL Dubai’s role in the overseas structure?

LPL Dubai is LPL’s wholly owned subsidiary and is the vehicle for strategic investments in diagnostics and allied activities. It was incorporated on June 12, 2026, under the Company Regulations of the DMCC Authority in Dubai, United Arab Emirates.

LPL Dubai had no applicable turnover because it was incorporated on June 12, 2026. LPL said the Dubai entity has already invested in Sunshine Healthcare, making the Ghanaian healthcare diagnostics business a subsidiary of LPL Dubai. The disclosed structure therefore places LPL Dubai between LPL and Sunshine Healthcare.

The proposed funding is a related-party transaction because LPL Dubai is wholly owned by LPL, and LPL said the transactions will be conducted on an arm’s-length basis. The filing does not disclose the number of Sunshine Healthcare shares involved in the further investment, its valuation, or a revised ownership percentage in the Ghana business.

What business does Sunshine Healthcare operate in Ghana?

Sunshine Healthcare provides healthcare and diagnostics services in Ghana and operates in the healthcare diagnostics industry. It was incorporated on September 7, 2010, under Ghanaian law, giving it a longer operating history than LPL Dubai, which was formed in June 2026.

Sunshine Healthcare reported turnover of Rs 24.4 crore in FY 26, compared with Rs 24 crore in FY 25 and Rs 21.7 crore in FY 24. Turnover rose by Rs 0.4 crore between FY 25 and FY 26, following a Rs 2.3 crore increase between FY 24 and FY 25.

The three-year record shows turnover increasing in each of the periods disclosed. LPL did not provide Sunshine Healthcare’s profit, assets, diagnostic-test volumes, network size, customer mix or specific deployment plan for the up to Rs 30 crore further investment.

When will LPL complete the proposed investment?

LPL expects the transaction to be completed by March 31, 2027, or on another date mutually agreed by the parties. The disclosed Rs 49.5 crore is a maximum investment amount rather than a confirmed single payment, and the timetable remains subject to the stated completion conditions.

LPL said it will obtain approvals from relevant authorities if they are required in the applicable jurisdictions. The filing does not name a specific regulator, identify an approval status, or set a closing date before March 31, 2027.

The consideration is cash, not a share swap, and LPL Dubai will continue as LPL’s wholly owned subsidiary. The disclosure also does not state a purchase price for Sunshine Healthcare shares or a valuation for either LPL Dubai or Sunshine Healthcare.

Conclusion

LPL’s approved overseas funding sets a maximum cash commitment of Rs 49.5 crore through LPL Dubai, including up to Rs 30 crore for further investment in Sunshine Healthcare. The structure uses the Dubai subsidiary for strategic diagnostics and allied-activity investments, while Sunshine Healthcare reported FY 26 turnover of Rs 24.4 crore.

The next disclosed milestone is expected completion by March 31, 2027, subject to any required regulatory approvals or another mutually agreed date. The key items to watch are the final amount invested against the Rs 49.5 crore ceiling, confirmation of approvals and any later disclosure on Sunshine Healthcare’s ownership or use of funds.